Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316352 | 0.86 | MCOLN3 (0.35) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL28974583 | 0.84 | HCRTR1 (0.32) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL28974542 | 0.84 | HCRTR1 (0.32) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL28974539 | 0.84 | HCRTR1 (0.32) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL16892828 | 0.83 | GAA (0.33) | L3MBTL1GAAKMT2AALDH1A1POLB | |
| SCHEMBL28413112 | 0.82 | ALDH1A1 (0.35) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL8445070 | 0.81 | L3MBTL1 (0.40) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL6086222 | 0.79 | PTGDR2 (0.42) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL17476551 | 0.78 | ALDH1A1 (0.36) | L3MBTL1MCOLN3USP2GAAKMT2A | |
| SCHEMBL17316523 | 0.78 | ALDH1A1 (0.34) | L3MBTL1MCOLN3USP2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382205-B1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI SA (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-2382205-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076524-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | HIF1AN, HIF1A, EGLN2 | L3MBTL1 3650/4885MCOLN3 4820/4885USP2 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.